Study confirms relevance of SVR endpoint for patients receiving HCV treatment

SVR, which has been challenged in regard to its association with clinical outcomes, has been confirmed as a prognosis-altering endpoint in patients with hepatitis C virus, according to findings published in Clinical Infectious Diseases.
As a result, SVR can serve as a surrogate endpoint that results in better clinical outcomes, according to the study results.
“Despite a lot of data showing the benefits of SVR in terms of both liver and non-liver-related outcomes, some have still argued that SVR is not a clinically important endpoint. They have made the case that, although studies have

Source link

Related posts

Genetics and pathophysiology of pancreatitis


REP2139 demonstrates functional cure in both HBV, HDV


Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction, Based on IBS in America Survey


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy